

Operating Room Elements

Depth of Anesthesia



Reduce POCD



Short Acting Anesthetic

Agents

- Timing
- Compliance



Glycemic Control

Maintain glucose in target
 range

VCUHealth




Fluids / Hemodynamics


- Optimize Flow
- Optimize Pressure




Opioid Sparing Analgesia

- Epidural / Spinal / Blocks
- Lidocaine Infusions
- Dexmedetomidine
- Ketamine








ERAS AND FLUID THERAPY RATIONALE





Avoid Fluid Shifts Avoid bowel prep Oral carbohydrate drink upto 2 hours preop Reduction of bowel handling and tissue injury– laparoscopic or laparoscopic assisted surgery Reduce blood loss	Individualised goal directed fluids to Maintain normovolemia Maintain hematocrit Optimise DO2i Maintain MAP >65-70mmHg Postoperative • Restrict salt and IV fluid • Maintain normovolaemia • Early enteral feeding
 The following significantly effect flui open surgery / prolonged surgery blood loss prolonged SIRS, or sepsis 	d shifts / requirements:













Advanced Hemodynamic Monitoring and Dvnamic Parameters



Esophageal Doppler Pleth Variabiliy Index Pulse Contour Wave Analysis Pulse Power Analysis PPV / SVV Bioreactance







Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery

P.S. Myles, R. Bellomo, T. Corcoran, A. Forbes, P. Peyton, D. Story, C. Christophi, K. Leslie, S. McGuinness, R. Parke, J. Serpell, M.T.V. Chan, T. Painter, S. McCluskey, G. Minto, and S. Wallace, for the Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group*

> The NEW ENGLAND JOURNAL of MEDICINE

BACKGROUND

Guidelines to promote the early recovery of patients undergoing major surgery recommend a restrictive intravenous-fluid strategy for abdominal surgery. However, the supporting evidence is limited, and there is concern about impaired organ perfusion.

METHODS

In a pragmatic, international trial, we randomly assigned 3000 patients who had an increased risk of complications while undergoing major abdominal surgery to receive a restrictive or liberal intravenous-fluid regimen during and up to 24 hours after surgery. The primary outcome was disability-free survival at 1 year. Key secondary outcomes were acute kidney injury at 30 days, renal-replacement therapy at 90 days, and a composite of septic complications, surgical-site infection, or death.

Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery

P.S. Myles, R. Bellomo, T. Corcoran, A. Forbes, P. Peyton, D. Story, C. Christophi, K. Leslie, S. McGuinness, R. Parke, J. Serpell, M.T.V. Chan, T. Painter, S. McCluskey, G. Minto, and S. Wallace, for the Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group*

RESULTS

During and up to 24 hours after surgery, 1490 patients in the restrictive fluid group had a median intravenous-fluid intake of 3.7 liters (interquartile range, 2.9 to 4.9), as compared with 6.1 liters (interquartile range, 5.0 to 7.4) in 1493 patients in the liberal fluid group (P<0.001). The rate of disability-free survival at 1 year was 81.9% in the restrictive fluid group and 82.3% in the liberal fluid group (hazard ratio for death or disability, 1.05; 95% confidence interval, 0.88 to 1.24; P=0.61). The rate of acute kidney injury was 8.6% in the restrictive fluid group and 5.0% in the liberal fluid group (P<0.001). The rate of septic complications or death was 21.8% in the restrictive fluid group and 19.8% in the liberal fluid group (P=0.19); rates of surgical-site infection (16.5% vs. 13.6%, P=0.02) and renal-replacement therapy (0.9% vs. 0.3%, P=0.048) were higher in the restrictive fluid group, but the between-group difference was not significant after adjustment for multiple testing.

21

Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery

P.S. Myles, R. Bellomo, T. Corcoran, A. Forbes, P. Peyton, D. Story, C. Christophi, K. Leslie, S. McGuinness, R. Parke, J. Serpell, M.T.V. Chan, T. Painter, S. McCluskey, G. Minto, and S. Wallace, for the Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group*


Variable	Restrictive Fluid (N=1490)	Liberal Fluid (N=1493)	P Value
During surgery			
Median intraoperative blood loss (IQR) — ml	200 (100 to 400)	200 (100 to 500)	0.14†
Median intraoperative fluid administration (IQR) — ml			
Crystalloid	1677 (1173 to 2294)	3000 (2100 to 3850)	< 0.001
Colloid‡	500 (250 to 800)	500 (400 to 1000)	0.01
Median infusion rate (IQR) — ml/kg/hr	6.5 (5.1 to 8.4)	10.9 (8.7 to 13.5)	< 0.001
In PACU§			
Median administration of fluid (IQR) — ml			
Crystalloid	160 (90 to 302)	300 (160 to 500)	< 0.001
Colloid±	400 (250 to 500)	500 (250 to 500)	0.27

Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery

P.S. Myles, R. Bellomo, T. Corcoran, A. Forbes, P. Peyton, D. Story, C. Christophi, K. Leslie, S. McGuinness, R. Parke, J. Serpell, M.T.V. Chan, T. Painter, S. McCluskey, G. Mirto, and S. Wallace, for the Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group^a

Postoperative day 1, post-PACU			
Median administration of fluid (IQR) — ml			
Crystalloid	1556 (1200 to 1960)	2600 (2052 to 3150)	< 0.001
Colloid‡	500 (250 to 1000)	500 (400 to 750)	0.89
Median infusion rate (IQR) — ml/kg/hr	0.9 (0.7 to 1.2)	1.5 (1.2 to 1.7)	< 0.001
At 24 hr after surgery			
Median cumulative total for intravenous fluids (IQR) — ml	3671 (2885 to 4880)	6146 (5000 to 7410)	<0.001
Median fluid balance (IQR) — ml¶	1380 (540 to 2338)	3092 (2010 to 4241)	<0.001†
Median weight gain (IQR) — kg	0.3 (-1.0 to 1.9)	1.6 (0.0 to 3.6)	ND


iubgroup	Restrictive Fluid	Liberal Fluid			Haz	ard Ratio	(95% CI)		P Value	P Value for Interaction
	no. of patient	s/total no.								
All patients	271/1490	262/1493						1.05 (0.88-1.24)	0.61	
Age										0.46
≤60 yr	66/441	70/435						0.93 (0.66-1.30)	0.68	
61-70 yr	74/367	60/380						1.32 (0.94-1.86)	0.11	
71-75 yr	43/308	47/313						0.93 (0.62-1.41)	0.74	
>75 yr	88/374	85/365						1.01 (0.73-1.36)		
Sex		,								0.03
Male	119/771	138/783						0.86 (0.67-1.10)	0.24	
Female	152/719	124/710				_		1.25 (0.99-1.58)		
ASA status										0.89
1 or 2	75/567	70/561			_	-		1.07 (0.78-1.49)	0.67	
3	174/849	172/868			-			1.05 (0.85-1.29)		
4	22/74	20/64		_				0.91 (0.50-1.66)		
Body-mass index		20/01			_				0.110	0.78
≤18.5	5/30	5/26	_		_		-	0.85 (0.25-2.94)	0.80	
>18.5-25.0	70/343	60/349			_	_		1.23 (0.87-1.73)		
>25.0-30.0	62/392	69/390						0.89 (0.63-1.26)		
>30.0-35.0	59/298	56/293			_	-		1.03 (0.71-1.48)		
>35.0	74/426	72/434			_			1.06 (0.76-1.46)		
Country	74/420	12/454			- E			1.00 (01/0-11/0)	0.75	0.047
Australia	152/836	159/841			_			0.96 (0.77-1.20)	0.75	0.047
New Zealand	14/46	3/48			-			5.59 (1.61-19.5)		
Hong Kong	16/111	9/116				_		1.92 (0.85-4.34)		
United Kingdom	28/141	36/134						0.71 (0.43-1.16)		
Italy	4/32	5/32					-	0.80 (0.22-2.99)		
United States	14/74	11/75						1.33 (0.61-2.94)		
Canada	43/250	39/247						1.12 (0.73-1.73)		
Colorectal surgery	43/230	39/24/						1.12 (0.75-1.75)	0.81	0.68
Yes	133/646	125/651						1.09 (0.85-1.39)	0.51	0.68
No					1			1.05 (0.80-1.28)		
No Planned GD device	138/844	137/842						1.03 (0.80-1.28)	0.93	0.83
Yes					_			0.00.40.61.1.63		0.83
Yes	31/185 240/1305	32/190 230/1303						0.99 (0.61-1.63)		
No Planned destination	240/1305	230/1303						1.05 (0.88-1.26)	0.58	0.74
ICU or HDU	125/429	122/422			1			1 01 (0 70 1 20)	0.07	0.74
Ward	125/429	122/422 140/1071						1.01 (0.78-1.29) 1.07 (0.85-1.34)		
Duration of surgery	146/1061	140/10/1						1.07 (0.85-1.34)	0.59	0.43
					-			1.11 (0.81-1.51)		0.43
≤2.5 hr >2.5–3.5 hr	85/436 61/416	73/410				_		0.92 (0.65-1.31)		
		66/412								
>3.5-4.5 hr	34/253	51/312			_			0.81 (0.52-1.25)		
>4.5 hr	91/385	72/359	_					1.20 (0.88-1.64)	0.24	
			0.2	0.4	1.0	2.0	4.0	8.0		
			Restric	tive Fluid	Better	Liberal F	luid Bette	-		
							bette	-		
	i for Death or Di									



Characteristic	Restrictive Fluid (N = 1490)	Liberal Fluid (N=1493)	
Mean age ±SD — yr	66±13	66±13	
Male sex — no. (%)	771 (51.7)	783 (52.4)	
Median body weight (IQR) — kg	84 (68–102)	<mark>(83)</mark> (69–102)	
ASA physical status — no. (%)†			
1	25 (1.7)	21 (1.4)	
2	542 (36.4)	540 (36.2)	
3	849 (57.0)	868 (58.1)	
At 24 hr after surgery	74 (5 0)	64 (4 3)	
Median cumulative total for intravenous fluids (IQR) — ml	3671 (2885 to 4880)	6146 (5000 to 7410)	<
<mark>(Median fluid balance</mark> (IQR) — ml¶	1380 (540 to 2338)	3092 (2010 to 4241)	<0
<mark>(Median weight gain</mark> (IQR) — kg∥	0.3 (-1.0 to 1.9)	1.6 (0.0 to 3.6)	
Fluid Balance at end of 24 hours	3.6 mls/kg	19.2 mls/kg	

Characteristic	Restrictive Fluid (N=1490)	Liberal Fluid (N=1493)	
Mean age ±SD — yr	66±13	66±13	
Male sex — no. (%)	771 (51.7)	783 (52.4)	
Median body weight (IQR) — kg	84 (68–102)	<mark>(83)</mark> (69–102)	
ASA physical status — no. (%)†			
1	25 (1.7)	21 (1.4)	
2	542 (36.4)	540 (36.2)	
3	849 (57.0)	868 (58.1)	
At 24 hr after surgery	74 /5 0)	64 (4 3)	I
Median cumulative total for intravenous fluids (IQR) — ml	3671 (2885 to 4880)	6146 (5000 to 7410)	<0.
<mark>Median fluid balance</mark> (IQR) — ml¶	<mark>1380</mark> (540 to 2338)	(2010 to 4241)	<0.0
(Median weight gain) (IQR) — kg	0.3 (-1.0 to 1.9)	1.6 (0.0 to 3.6)	N
Fluid Balance at end of 24	3.6 mls/kg	19.2 mls/kg	
My Interpretation: hours Study does not show near zero balance increases optimization above the risk zone of AKI was not m Study does reinforce that provided patient lands b not an issue	napped		e





WHAT MEAN ARTERIAL PRESSURE MATTERS?

29

Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery

A Retrospective Cohort Analysis

Vafi Salmasi, M.D., Kamal Maheshwari, M.D., M.P.H., Dongsheng Yang, M.A., Edward J. Mascha, Ph.D., Asha Singh, M.D., Daniel I. Sessler, M.D., Andrea Kurz, M.D.


ABSTRACT

Background: How best to characterize intraoperative hypotension remains unclear. Thus, the authors assessed the relationship between myocardial and kidney injury and intraoperative absolute (mean arterial pressure [MAP]) and relative (reduction from preoperative pressure) MAP thresholds.

Methods: The authors characterized hypotension by the lowest MAP below various absolute and relative thresholds for cumulative [1, 3, 5, or 10 min and also time-weighted average below various absolute or relative MAP thresholds. The authors modeled each relationship using logistic regression. The authors further evaluated whether the relationships between intraoperative hypotension and either myocardial or kidney injury depended on baseline MAP. Finally, the authors compared the strength of associations between absolute and relative thresholds on myocardial and kidney injury using C statistics.

Results: MAP below absolute thresholds of 65 mmHg or relative thresholds of 20% were progressively related to both myocardial and kidney injury. At any given threshold, prolonged exposure was associated with increased odds. There were no clinically important interactions between preoperative blood pressures and the relationship between hypotension and myocardial or kidney injury at intraoperative mean arterial blood pressures less than 65 mmHg. Absolute and relative thresholds had comparable ability to discriminate patients with myocardial or kidney injury from those without.

Conclusions: The associations based on relative thresholds were no stronger than those based on absolute thresholds. Furthermore, there was no clinically important interaction with preoperative pressure. Anesthetic management can thus be based on intraoperative pressures without regard to preoperative pressure. **(ANESTHESIOLOGY 2017; 126:47-65)**








Fig. 3. The lowest mean arterial pressure (MAP) thresholds for acute kidney injury (AKI). Univariable and multivariable relationship between AKI and absolute and relative lowest MAP thresholds. (A) and (C) Estimated probability of AKI were from the univariable moving-window with the width of 10% data; (B) and (D) were from multivariable logistic regression smoothed by restricted cubic spline with three degrees and knots at 10th, 50th, and 90th percentiles of given exposure variable. Multivariable models adjusted for covariates in table 1. (A) and (B) show that there was a change point (*i.e.*, decreases steeply up and then flattens) around 65 mmHg, but 20% was not a change point from (C) and (D).

Effect of India Management Among High- A Randomizer	tien I Cambro Too The Cambro Link INTERNET
	IMPORTANCE Perioperative hypotension is associated with an increase in postoperative morbidity and mortality, but the appropriate management strategy remains uncertain.
	OBJECTIVE To evaluate whether an individualized blood pressure management strategy tailored to individual patient physiology could reduce postoperative organ dysfunction.
	DESIGN, SETTING, AND PARTICIPANTS The Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) study was a multicenter, randomized, parallel-group clinical trial conducted in 9 French university and nonuniversity hospitals. Adult patients (n = 298) at increased risk of postoperative complications with a preoperative acute kidney injury risk index of class III or higher (indicating moderate to high risk of postoperative kidney injury) undergoing major surgery lasting 2 hours or longer under general anesthesia were enrolled from December 4, 2012, through August 28, 2016 (last follow-up, September 28, 2016).
	INTERVENTIONS Individualized management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the reference value (ie, patient's resting SBP) or standard management strategy of treating SBP less than 80 mm Hg or lower than 40% from the reference value during and for 4 hours following surgery.


AMA 1 Opportunity and the CAMBRETORY THE CHITCALLY LLANTERY Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery A Randomized Clinical Trial

RESULTS Among 298 patients who were randomized, 292 patients completed the trial (mean [SD] age, 70 [7] years; 44 [15.1%] women) and were included in the modified intention-to-treat analysis. The primary outcome event occurred in 56 of 147 patients (38.1%) assigned to the individualized treatment strategy vs 75 of 145 patients (51.7%) assigned to the standard treatment strategy (relative risk, 0.73; 95% CI, 0.56 to 0.94; P = .02; absolute risk difference, -14%, 95% CI, -25% to -2%). Sixty-eight patients (46.3%) in the individualized treatment group and 92 (63.4%) in the standard treatment group had postoperative organ dysfunction by day 30 (adjusted hazard ratio, 0.66; 95% CI, 0.52 to 0.84; P = .001). There were no significant between-group differences in severe adverse events or 30-day mortality.


CONCLUSIONS AND RELEVANCE Among patients predominantly undergoing abdominal surgery who were at increased postoperative risk, management targeting an individualized systolic blood pressure, compared with standard management, reduced the risk of postoperative organ dysfunction.

AMA I organized investigation I CARREGOR THE CRITICALLYILL RATION Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery A Randomized Clinical Trial


Emissional Faller, MD, PhD, Jano Ywai, Jadram, MD, PhD, Jamo Gorgen Gunza, MD, PHD, Tamena Gord, MJ, PHD, Simmanal Lones, MD, Bernard MD, Sellow MD, Sellow MD, MD, MD, MD, Sellow S, Sharing MD, Shar





A Original Investigation CARING FOR THE CRITICALLY ILL PATIE							
fect of Individualized vs Standard B		·					
anagement Strategies on Postopera nong High-Risk Patients Undergoin							
Randomized Clinical Trial	Ig Major Surgery	8					
anuel Futier, MD, PhD, Jean-Yves Lefrant, MD, PhD, Pierre-Gregoire Guinot, MD, PhD, 1	Thomas Godet, MD, PhD; Emmanuel Li	ome.MD/					
upe Currillon, MD, PhD, Sebastien Bertran, MD, Marc Leone, MD, PhD, Bruno Pastere, M es Albanese, MD, PhD, avan-Michel Aula, MD, Benot Toverner, MD, PhD, Eternie HM Michel Constantin, MD, PhD, Bruno Peretra, PhD, Samer Jalae, MD, PhD, for the INPRIM Alchel Constantin, MD, IPhD, Bruno Peretra, PhD. Samer Jalae, MD, PhD, for the INPRIME.	MD: Vincent Piriou, MD, PhD: Serge Moli hoff, MD: Jean-Etienne Bazin, MD, PhD:	Bes. MD. PhD:					
	15 Stildy Group						
Acute kidney injury according to RIFLE criteria, No. (%) ^d							
Risk	23 (15.7)	36 (24.8)	-9 (-18 to 0)	0.63 (0.39 to 1.00)	.05	0.73 (0.47 to 1.14)	.17
Injury	16 (10.9)	26 (17.9)	-7 (-15 to 1)	0.61 (0.34 to 1.08)	.09	0.61 (0.34 to 1.08)	.09
Failure	9 (6.1)	9 (6.2)	0 (-6 to 5)	0.99 (0.40 to 2.41)	.98	0.97 (0.40 to 2.34)	.95
Use of renal replacement therapy, No. (%)	4 (2.7)	5 (3.5)	0 (-5 to 3)	0.79 (0.22 to 2.88)	.72	0.81 (0.22 to 2.97)	.76
Acute heart failure, No. (%)	1 (0.7)	0	1 (-1 to 2)				
Myocardial ischemia or infarction, No. (%)	0	1 (0.7)	-1 (-2 to 1)				
Altered consciousness, No. (%) ^e	8 (5.4)	23 (15.9)	-10 (-17 to -3)	0.34 (0.16 to 0.74)	.007	0.34 (0.16 to 0.75)	.007
Stroke, No. (%)	0	0					
Coagulation SOFA score ≥2, No. (%)	16 (11.0)	11 (7.6)	3 (-3 to 10)	1.44 (0.69 to 3.01)	.33	1.47 (0.07 to 2.23)	.07
Hypoxemia, No. (%)	21 (14.3)	33 (22.8)	-8 (-17 to 0)	0.63 (0.38 to 1.03)	.07	0.64 (0.40 to 1.03)	.07
Pneumonia, No. (%)	4 (2.7)	11 (7.6)	-5 (-10 to 0)	0.36 (0.12 to 1.10)	.07	0.36 (0.12 to 1.10)	.07
ARDS, No. (%)	7 (4.8)	7 (4.8)	0 (-5 to 5)	0.99 (0.35 to 2.74)	.98	0.98 (0.35 to 2.67)	.95
Reintubation, No. (%)	10 (6.8)	15 (10.3)	-4 (-10 to 3)	0.66 (0.31 to 1.42)	.28	0.66 (0.31 to 1.42)	.28
Need for noninvasive or invasive ventilation, No. (%)	25 (17.0)	36 (24.8)	-8 (-17 to 1)	0.68 (0.43 to 1.08)	.10	0.71 (0.45 to 1.11)	.13
SOFA score, median (IQR) ^f							
Day 1	1 (0-3)	1 (0-3)			.31		.36
Day 2	1 (0-2)	2 (0-3)			.19		.21
Day 7	0 (0-1)	0 (0-1)			.66		.68
Sepsis, No. (%)	13 (8.8)	23 (15.9)	-7 (-15 to 0)	0.56 (0.29 to 1.06)	.07	0.55 (0.29 to 1.04)	.07
Severe sepsis or septic shock,	13 (8.8)	13 (9.0)	0 (-6 to 7)	0.99 (0.47 to 2.05)	.97	1.01 (0.49 to 2.11)	.97




Summary - MAP If MAP is reduced below 65mmHg there is an increase risk of: Kidney Injury / AKI Delirium Myocardial Injury / MINS (Infection) The effect is increased by duration and magnitude below 65mmHg An individulaised MAP target may be beneficial but flow must be optimized first (so may not be just a pressure effect)










Summary - ERAS Fluid 'Road Map' Euvolemia at start of surgery – carbohydrate loading Use hemodynamic monitors to ensure patient's intravascular volume is optimized after induction of anesthesia prior to surgery +/- pneumoperitoneum Range 7-12mls/kg Bet your starting Stroke Volume as baseline and Cardiac Output with Heart Rate = flow = oxygen delivery Then set MAP with low dose vasopressors Maintainance at 2-4ml/kg / hour Reptone stroke volume at end of surgery – back to your starting Stroke volume Tageted fluid boluses in post operative 6 hours +/- low dose vasopressors if needed (if high boluos, SIRS or epidural) Iv maintenance of balanced IV fluid at 1ml/kg /hour until morning of PO 1 – then take IVI down as patient should be drinking





PeriOperative Quality Improvement POQI Group: Analgesia within a Colorectal Surgery ERP CONSENSUS CONSENSUS en Access en Access American Society for Enhanced Recovery American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on (POQI) Joint Consensus Statement on optimal analgesia within an enhanced Optimal Analgesia within an Enhanced recovery pathway for colorectal surgery: Recovery Pathway for Colorectal Surgery: part 1—from the preoperative period to Part 2—From PACU to the Transition Home PACU Michael J. Scott¹²¹, Matthew D. McEvoy³⁴¹, Debra B. Gordon⁵, Stuart A. Grant⁶, Julie K. M. Thacker⁷, Christopher L. Wi⁴⁷, Tong J. Gan⁴, Monty G. Mythen¹⁰, Andrew D. Shaw¹¹, Timothy E. Miller¹²⁴ and For the Periopentive Quality Initiative (POOI) I Workgroup. Matthew D. McEvoy¹¹, Michael J. Scott^{2,3,41}, Debra B. Gordon⁹, Stuart A. Grant⁶, Julie K. M. Thacker⁷, Christopher L. Wu², Tong J. Gan⁶, Monty G. Mythen⁹, Ardrew D. Shaw¹¹, Timothy E. Miller^{2,2} and For the Fertoperative Quality Initiative (POOJ) I Workgroup. TREATMENT ALGORITHM FOR ACHIEVING OPTIMAL ANALGESIA AFTER COLORECTAL SURGERY **Optimal Analgesia After Surgery** PREOP HOLDING ating Solid Foods Encourages Postoperative DREAMS VCUHealth.














Summary

- 1. Enhanced Recovery after Surgery (ERAS)pathways mitigate many factors to reduce complications
- 2. The anesthesiologist / CRNA plays a key role in:
- Preoperative Optimization
- Standardized
- Goal Directed Hemodynamic Strategy
- Opioid Sparing Analgesia

